share_log

The Strong Earnings Posted By Neurocrine Biosciences (NASDAQ:NBIX) Are A Good Indication Of The Strength Of The Business

The Strong Earnings Posted By Neurocrine Biosciences (NASDAQ:NBIX) Are A Good Indication Of The Strength Of The Business

Neurocrine Biosciences(納斯達克股票代碼:NBIX)公佈的強勁收益很好地表明瞭該業務的實力
Simply Wall St ·  02/16 05:36

Investors were underwhelmed by the solid earnings posted by Neurocrine Biosciences, Inc. (NASDAQ:NBIX) recently. We have done some analysis and have found some comforting factors beneath the profit numbers.

投資者對Neurocrine Biosciences, Inc.(納斯達克股票代碼:NBIX)最近公佈的穩健收益感到不知所措。我們已經進行了一些分析,發現利潤數字之下有一些令人欣慰的因素。

earnings-and-revenue-history
NasdaqGS:NBIX Earnings and Revenue History February 16th 2024
NASDAQGS: NBIX 收益和收入歷史記錄 2024 年 2 月 16 日

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

For anyone who wants to understand Neurocrine Biosciences' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by US$116m due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Neurocrine Biosciences to produce a higher profit next year, all else being equal.

對於任何想了解法定數字之外的Neurocrine Biosciences利潤的人來說,值得注意的是,在過去的十二個月中,由於異常項目,法定利潤減少了1.16億美元。看到不尋常的項目使公司利潤付出代價從來都不是一件好事,但從好的方面來看,情況可能遲早會好轉。我們調查了數千家上市公司,發現不尋常的物品本質上往往是一次性的。而且,畢竟,這正是會計術語的含義。假設這些不尋常的支出不會再次出現,因此,我們預計Neurocrine Biosciences在其他條件相同的情況下,明年將實現更高的利潤。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On Neurocrine Biosciences' Profit Performance

我們對Neurocrine Biosciences盈利表現的看法

Unusual items (expenses) detracted from Neurocrine Biosciences' earnings over the last year, but we might see an improvement next year. Because of this, we think Neurocrine Biosciences' earnings potential is at least as good as it seems, and maybe even better! And on top of that, its earnings per share increased by 58% in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. Every company has risks, and we've spotted 2 warning signs for Neurocrine Biosciences you should know about.

去年,不尋常的項目(支出)減少了Neurocrine Biosciences的收益,但明年我們可能會看到改善。因此,我們認爲Neurocrine Biosciences的盈利潛力至少和看起來一樣好,甚至可能更好!最重要的是,其每股收益在去年增長了58%。歸根結底,如果你想正確地了解公司,必須考慮的不僅僅是上述因素。有鑑於此,如果你想對公司進行更多分析,了解所涉及的風險至關重要。每家公司都有風險,我們發現了兩個你應該知道的Neurocrine Biosciences警告信號。

This note has only looked at a single factor that sheds light on the nature of Neurocrine Biosciences' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

這份報告只研究了揭示Neurocrine Biosciences利潤性質的單一因素。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論